<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143430">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233609</url>
  </required_header>
  <id_info>
    <org_study_id>H-13371</org_study_id>
    <nct_id>NCT01233609</nct_id>
  </id_info>
  <brief_title>Trial of Oral Valproic Acid for Retinitis Pigmentosa</brief_title>
  <acronym>VPA</acronym>
  <official_title>A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation Fighting Blindness Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation Fighting Blindness Clinical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both
      slow the progression of visual function loss and/or to restore visual function in patients
      with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability
      information.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis Pigmentosa (RP) is an incurable and untreatable group of heterogeneous retinal
      degenerative diseases that cause severe visual loss. There is currently no therapeutic that
      substantially slows the progression of this disease, and certainly none that can restore
      vision in RP patients. The Valproic Acid (VPA) study is designed as a six-site,
      interventional, prospective, randomized, placebo controlled, double-blinded study of 90
      participants to evaluate the efficacy of oral Valproic Acid to both slow the progression of
      visual function loss and/or to restore visual function in patients with an Autosomal
      Dominant RP genetic mutation and to collect safety and tolerability information. Patients
      that participate in the study will be randomized to either placebo or VPA in a 1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in visual field area from baseline to 52 weeks.</measure>
    <time_frame>Screening, baseline, week 26, and week 52</time_frame>
    <description>Mean change in visual field area from baseline to 52 weeks. Visual field area will be measured using semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haig-Strait).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Static perimetry measurements in the full visual field</measure>
    <time_frame>Screening, baseline, week 26, and week 52</time_frame>
    <description>Static perimetry measurements in the full visual field, including the central 30 field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in best corrected visual acuity.</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Mean change in best corrected visual acuity as measured by Electronic Visual Acuity-Early Treatment Diabetic Retinopathy Study (EVA-ETDRS) visual acuity test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color contrast sensitivity</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Color contrast sensitivity as measured by ChromaTest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in peak Electroretinogram (ERG) amplitude</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Mean change in peak Electroretinogram (ERG) amplitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in central macular thickness and macular volume</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Mean change in central macular thickness and mean change in macular volume as measured by Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fundus appearance</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Change in fundus appearance as judged by color retinal photography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in total score on vision-related quality of life.</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>Mean change in total score on vision-related quality of life as measured by the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory data</measure>
    <time_frame>Baseline through 15 months</time_frame>
    <description>Changes in clinical laboratory data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical examination findings</measure>
    <time_frame>Baseline through 15 months</time_frame>
    <description>Changes in physical examination findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Valproic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who receive valproic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>One to four 250mg softgels by mouth daily (dose determined by body weight)</description>
    <arm_group_label>Valproic Acid</arm_group_label>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage per subject weight- same schedule as the active comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand/sign the IRB-approved study informed consent document.

          2. Age greater than or equal to 18 years, no upper age limit

          3. Males and non-child bearing females must weigh ≥40 Kg and ≤158.9 Kg; Females of child
             bearing potential must weigh ≥40 Kg and ≤74.9 Kg.

          4. Diagnosis of Retinitis Pigmentosa (RP).

          5. Visual acuity of greater than or equal to 35 letters in at least one eye as measured
             by the EVA-ETDRS (equivalent to 20/200 on a Snellen chart).

          6. Genotyped as autosomal dominant form of RP.

          7. Female subjects of childbearing potential and male subjects able to father children
             must have (or have a partner who has) had a hysterectomy or vasectomy, be completely
             abstinent from intercourse or must commit to practice at least two acceptable methods
             of contraception to minimize the chance of pregnancy during the study and for the 13
             week period after stopping the study drug.

          8. Female subjects of childbearing potential must have a negative urine pregnancy test
             at study entry and throughout the duration of the study.

          9. Willingness to comply with the protocol.

        Exclusion Criteria:

          1. Medical problems that make consistent follow-up over the treatment period unlikely
             (e.g. stroke, severe MI, end stage malignancy), or in general a poor medical risk
             because of other systemic diseases or active uncontrolled infections.

          2. Other retinal diseases: Glaucoma, retinal inflammatory disease (CME is allowable),
             cataract worse than +2 NS, or herpes simplex virus of the eye.

          3. Intact visual field of 5⁰ or less.

          4. Subject unable to provide reliable perimetry measurements in both eyes for both
             static and kinetic visual field, as determined by the Reading Center.

          5. Diabetes.

          6. History of cancer (other than non-melanoma skin cancer) diagnosed, or requiring
             treatment within the past 2 years.

          7. A hemoglobin concentration, a platelet count or an absolute neutrophil count below
             the lower limit of normal at study entry.

          8. Suspected liver dysfunction determined by having liver function values elevated above
             the upper limit of normal.

          9. History of pancreatitis by clinical features and/or laboratory abnormalities in the
             last 12 months.

         10. Renal dysfunction based on serum creatinine,(MDRD) equation.

         11. Urea cycle disorders.

         12. History of neurological conditions including epilepsy, history of brain injury,
             encephalitis, or any organic brain syndrome.

         13. History of schizophrenia, schizoaffective disorder, bipolar disorder, suicidality or
             organic mental disorders.

         14. Currently receiving valproic acid or other anti-convulsants.

         15. Sensitive to or have ever had an allergic reaction to valproic Acid.

         16. Sensitive to or have ever had an allergic reaction to peanuts as peanut oil is an
             inactive ingredient in valproic acid capsules and the placebo.

         17. Has taken one of the disallowed drugs at least 2 weeks prior to randomization.

         18. Pregnant women.

         19. Lactating mothers who are breast feeding their babies.

         20. RP patients involved in other clinical trials within the last 3 months.

         21. Require enrollment by consent of a legally authorized representative.

         22. Persons who are unable to read are not allowed to consent for themselves or others to
             participate in this study.

         23. The potential participant lives in the same household as a current participant in
             this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Zilliox, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Foundation Fighting Blindness Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami, Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, Hamilton Eye Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine, Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.blindness.org/index.php?option=com_content&amp;view=section&amp;id=7&amp;itemid=101</url>
    <description>Click here for more information about this study: Clinical Trial page of the Foundation Fighting Blindness Website.</description>
  </link>
  <reference>
    <citation>Berson EL, Rosner B, Weigel-DiFranco C, Dryja TP, Sandberg MA. Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3027-36.</citation>
    <PMID>12202526</PMID>
  </reference>
  <reference>
    <citation>Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology. 1996 Feb;46(2):465-9.</citation>
    <PMID>8614514</PMID>
  </reference>
  <reference>
    <citation>Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol. 1985 Mar 15;99(3):240-51.</citation>
    <PMID>3976802</PMID>
  </reference>
  <reference>
    <citation>Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, Lu RB, Gean PW, Chuang DM, Hong JS. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007 Oct 12;149(1):203-12. Epub 2007 Jul 28.</citation>
    <PMID>17850978</PMID>
  </reference>
  <reference>
    <citation>Delyfer MN, Léveillard T, Mohand-Saïd S, Hicks D, Picaud S, Sahel JA. Inherited retinal degenerations: therapeutic prospects. Biol Cell. 2004 May;96(4):261-9. Review.</citation>
    <PMID>15145530</PMID>
  </reference>
  <reference>
    <citation>Dragunow M, Greenwood JM, Cameron RE, Narayan PJ, O'Carroll SJ, Pearson AG, Gibbons HM. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience. 2006 Jul 21;140(4):1149-56.</citation>
    <PMID>16600518</PMID>
  </reference>
  <reference>
    <citation>Gaby AR. Nutritional therapies for ocular disorders: Part Three. Altern Med Rev. 2008 Sep;13(3):191-204. Review.</citation>
    <PMID>18950246</PMID>
  </reference>
  <reference>
    <citation>Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001 Dec 17;20(24):6969-78.</citation>
    <PMID>11742974</PMID>
  </reference>
  <reference>
    <citation>Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809. Review.</citation>
    <PMID>17113430</PMID>
  </reference>
  <reference>
    <citation>Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37 Suppl 2:5-16. Review.</citation>
    <PMID>14624229</PMID>
  </reference>
  <reference>
    <citation>Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol. 2004 Apr;137(4):704-18.</citation>
    <PMID>15059710</PMID>
  </reference>
  <reference>
    <citation>Jacobson SG, Cideciyan AV, Huang Y, Hanna DB, Freund CL, Affatigato LM, Carr RE, Zack DJ, Stone EM, McInnes RR. Retinal degenerations with truncation mutations in the cone-rod homeobox (CRX) gene. Invest Ophthalmol Vis Sci. 1998 Nov;39(12):2417-26.</citation>
    <PMID>9804150</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007 Jun;321(3):892-901. Epub 2007 Mar 19.</citation>
    <PMID>17371805</PMID>
  </reference>
  <reference>
    <citation>Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators.. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001 Jul;119(7):1050-8.</citation>
    <PMID>11448327</PMID>
  </reference>
  <reference>
    <citation>Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3224-30. doi: 10.1167/iovs.07-1539. Epub 2008 Mar 31.</citation>
    <PMID>18378578</PMID>
  </reference>
  <reference>
    <citation>Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U. Comparison between semiautomated kinetic perimetry and conventional Goldmann manual kinetic perimetry in advanced visual field loss. Ophthalmology. 2005 Aug;112(8):1343-54.</citation>
    <PMID>15996734</PMID>
  </reference>
  <reference>
    <citation>Nowomiejska K, Vonthein R, Paetzold J, Zagorski Z, Kardon R, Schiefer U. Reaction time during semi-automated kinetic perimetry (SKP) in patients with advanced visual field loss. Acta Ophthalmol. 2010 Feb;88(1):65-9. doi: 10.1111/j.1755-3768.2008.01407.x. Epub 2009 Dec 16.</citation>
    <PMID>19094165</PMID>
  </reference>
  <reference>
    <citation>Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther. 2005 Oct;30(5):417-21. Review.</citation>
    <PMID>16164485</PMID>
  </reference>
  <reference>
    <citation>Wong R, Khan J, Adewoyin T, Sivaprasad S, Arden GB, Chong V. The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. BMC Ophthalmol. 2008 Aug 17;8:15. doi: 10.1186/1471-2415-8-15.</citation>
    <PMID>18706104</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 21, 2016</lastchanged_date>
  <firstreceived_date>November 1, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>valproic acid</keyword>
  <keyword>visual field</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
